Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 256 to 270 of 838 results for score

  1. Secca System for faecal incontinence (MIB66)

    NICE has developed a medtech innovation briefing (MIB) on the Secca System for faecal incontinence

  2. Patient Status Engine for wireless monitoring of vital signs (MIB271)

    NICE has developed a medtech innovation briefing (MIB) on the Patient Status Engine for wireless monitoring of vital signs .

  3. Setmelanotide for treating obesity caused by LEPR or POMC deficiency (HST21)

    Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity caused by LEPR or POMC deficiency in people 6 years and over.

  4. Tofacitinib for treating active ankylosing spondylitis (TA920)

    Evidence-based recommendations on tofacitinib (Xeljanz) for treating active ankylosing spondylitis.

  5. Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)

    Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults.

  6. Gastroparesis in adults: oral erythromycin (ESUOM13)

    Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making

  7. Open femoro–acetabular surgery for hip impingement syndrome (IPG403)

    Evidence-based recommendations on open femoro-acetabular surgery for hip impingement syndrome. This involves removing some of the cartilage or bone, with the aim of reshaping the joint surface.

  8. Ofatumumab for treating relapsing multiple sclerosis (TA699)

    Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.

  9. Partial replacement of the meniscus of the knee using a biodegradable scaffold (IPG430)

    Evidence-based recommendations on partial replacement of the meniscus of the knee using a biodegradable scaffold. This involves placing a biodegradable implant into the meniscus to support regrowth and repair of the damage.

  10. ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)

    NICE has developed a medtech innovation briefing (MIB) on ClearWay RX for drug delivery to coronary artery thrombotic lesions

  11. Arthroscopic trochleoplasty for patellar instability (IPG474)

    Evidence-based recommendations on arthroscopic trochleoplasty for patellar instability. This involves reshaping the bony anatomy of the trochlea by deepening the groove or elevating the lateral wall.

  12. Stockholm3 for prostate cancer screening (MIB303)

    NICE has developed a medtech innovation briefing (MIB) on Stockholm3 for prostate cancer screening .

  13. Avelumab for treating metastatic Merkel cell carcinoma (TA517)

    Evidence-based recommendations on avelumab (Bavencio) for metastatic Merkel cell carcinoma in adults.

  14. Soft-palate implants for obstructive sleep apnoea (IPG241)

    Evidence-based recommendations on soft-palate implants for obstructive sleep apnoea. This involves inserting implants into the soft palate of the mouth to stiffen it over subsequent weeks and make it less likely to vibrate.

  15. The Oncentra Prostate v4.x for ultrasound‑guided real‑time HDR brachytherapy in men with localised prostate cancer (MIB16)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Oncentra Prostate v4.x ultrasound-guided real-time HDR brachytherapy in men with localised